arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Barinthus Biotherapeutics plc.

BRNS
$0.60 0.00 (0.00%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
25 Visible periods
27 Metrics
Peer-ranked Benchmarks
Price Chart
21
Health
Poor
Bearish
auto_awesome

Analytical Summary

Barinthus Biotherapeutics plc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $24.5M
Dividend Yield
Revenue Growth None
Op. Margin None
ROIC -9.1%
FCF / Share $-0.08
Trailing P/E
Price / Book 0.4x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 3, 2026.

25-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
Net Income Profit after all expenses
$-5.53M
↑ +71.8%
Operating Margin Operating profit as % of sales
-62.7%
↑ +83.9%
FCF / Share Free cash flow per share
$-0.08
↑ +77.7%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
10
Cash Quality
50

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 6 years · 25 quarters